Status and phase
Conditions
Treatments
About
This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
45 participants in 1 patient group
Loading...
Central trial contact
Therapeutics Genfleet
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal